Sales of TriCor/TriLipix (which ABT treats as one franchise) grew slightly in 3Q11 to an annualized run rate of $1.7B. The damage from the failure in the ACCORD study (#msg-47808450) has not been as bad as I expected.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”